Hypertension (High Blood Pressure) News and Research

RSS

Hypertension (or high blood pressure) is a condition where the pressure of the blood flowing through the arteries of the body is higher than it should be. Much like the pressure of the air in a tire, if the pressure of the blood is too high it can damage the arteries and organs of the body. Just like the tire, if the pressure suddenly becomes very high, catastrophic events can happen. Similarly, if the pressure remains somewhat elevated for a long enough period of time, premature wear and failure can occur.

Hypertension has its worst effects on the heart, kidneys, eyes, and brain. High blood pressure is a risk factor for heart attack, stroke, kidney failure, hemorrhages of the retina of the eye, and generalized atherosclerosis (hardening of the arteries all over the body).

Jiangbo fourth-quarter revenues decrease 5.9% to $29.3M

Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced financial results for its fourth quarter and fiscal year ended June 30, 2010. The Company's annual report on Form 10-K has been filed with the U.S. Securities and Exchange Commission and is available on the Company's website.

30 Sep 2010

Tengion presents Neo-Kidney Augment development program at ISCT Symposium

Tengion, Inc. presented new research data yesterday in a podium presentation at the 2nd Annual Symposium on Stem Cell Translation of the International Society for Cellular Therapy (ISCT) in San Francisco. The presentation highlighted new results from Tengion's Neo-Kidney Augment development program demonstrating success with an autologous cellular therapy approach to kidney regeneration in a rodent model of obesity, diabetes and hypertension.

30 Sep 2010

Pulmokine receives NIH SBIR grants to develop novel treatments for PAH

YM BioSciences Inc., today reported that Pulmokine Inc. (Slingerlands, New York), a licensee of several small molecule compounds from YM, has been awarded two National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grants. The grants, totaling more than US$650,000, are Phase I awards to develop novel treatments for Pulmonary Arterial Hypertension (PAH).

29 Sep 2010

Hypertension drug market to decline by $3 billion in 2019: Decision Resources

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, owing to increasing generic availability of antihypertensive agents, the hypertension drug market will decline from $26 billion in 2009 to $23 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

29 Sep 2010

Endo Pharmaceuticals to acquire Qualitest Pharmaceuticals

Endo Pharmaceuticals announced today that it has entered into a definitive agreement to acquire Qualitest Pharmaceuticals, a leading, privately held generics company in the U.S., for approximately $1.2 billion in cash.

28 Sep 2010

Women & Infants Hospital receives $2.1M NIH grant to continue work under COBRE for Perinatal Biology

Women & Infants Hospital has recently received a $2.1 million grant from the National Institutes of Health to continue work under the Center of Biomedical Research Excellence for Perinatal Biology. Of the 108 COBREs across the country, Women & Infants is the only one specifically focused on developmental research.

28 Sep 2010

Experts predict rise in food prices

With food prices expected to rise by 50 per cent within 10 years experts are planning to discuss the issues in Brisbane. There is to be a three-day summit on food security this week. With the global population touching nine billion by 2050, Australia’s role in feeding the world will be explored.

27 Sep 2010

Clinical trial results of Genous Bio-engineered R stent, EPC capture technology presented at TCT 2010

OrbusNeich today announced that clinical trial results highlighting the company's Genous Bio-engineered R stent and its endothelial progenitor cell capture technology across challenging patient subsets were presented during a symposium titled "EPC Capture Technology: from Genous to Combo" at Transcatheter Cardiovascular Therapeutics 2010 in Washington.

27 Sep 2010

HHS awards grant to promote better primary care services for mentally-ill patients

Secretary of Health and Human Services Kathleen Sebelius today awarded more than $26.2 million in grants to support and promote better primary care and behavioral health services for individuals with mental illnesses or substance use disorders.

27 Sep 2010

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

Today Astellas Pharma US, Inc. announced results of a Phase IV study showing Lexiscan(regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or chronic obstructive pulmonary disease (COPD) who are likely candidates for myocardial perfusion imaging (MPI) studies.

27 Sep 2010

Malnutrition, inflammation complicate blood cholesterol readings in CKD patients

To understand the health effects of high cholesterol levels, doctors first need to assess malnutrition and inflammation status in their chronic kidney disease (CKD) patients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

24 Sep 2010

Preclinical data of novel drug-resistant hypertension therapy presented at TCT 2010

Preclinical data of a novel therapy designed to treat drug-resistant hypertension (high blood pressure) was presented Tuesday, September 21st, at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 Conference in Washington, DC, by Christopher D. Owens, MD, MSc, Assistant Professor in Residence, Division of Vascular and Endovascular Surgery, University of California, San Francisco.

24 Sep 2010

UC San Diego receives grant to study hypoxia susceptibility

Gabriel G. Haddad, MD, chair of the Department of Pediatrics at the University of California, San Diego School of Medicine and Physician-in-Chief at Rady Children's Hospital-San Diego has received a $10 million grant from the National Institute of Health's Heart, Lung and Blood Institute.

24 Sep 2010

Scientists discover molecular playbook to block cardiac hypertrophy

Like a well-crafted football play designed to block the opposing team's offensive drive to the end zone, the body constantly executes complex 'plays' or sequences of events to initiate, or block, different actions or functions.

24 Sep 2010

Negative childhood experiences impacting in the brains of Indigenous kids

Australia will not Close the Gap on Aboriginal health unless more is done to reverse the early life stress and trauma experienced by Indigenous children, new research suggests.

23 Sep 2010

Physicians' health habits could affect their abilities to counsel patients on diet, exercise

Physician's confidence in their abilities to counsel patients on a healthy diet and exercise may be related to their own personal habits, according to a study by the University of Michigan Cardiovascular Center.

23 Sep 2010

Resistance training program can help maintain metabolic health: Research

Although obesity is a major risk factor for disease, much of the threat may be associated with the metabolic (or cardiometabolic) syndrome, a cluster of risk factors related to diabetes and heart disease. Losing weight can improve health and reduce many of these risk factors. However, many people struggle to keep the weight off long-term.

23 Sep 2010

Phase II study: Fostamatinib improves outcomes in RA patients

AstraZeneca's new oral syk inhibitor, fostamatinib (R788), recently in-licensed from Rigel Pharmaceuticals, Inc., significantly improved outcomes of patients with rheumatoid arthritis who responded inadequately to ongoing treatment with methotrexate, according to phase II study data published in The New England Journal of Medicine today.

23 Sep 2010

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.

23 Sep 2010

Hyponatremia may lead to neurological complications

A new study published in the October issue of the journal Hepatology found that patients with severe portal-hypertensive bleeding who are treated with terlipressin may experience an acute reduction of sodium in their blood. This reduction in serum sodium, known as hyponatremia, can cause adverse reactions such as neurological complications, and is rapidly reversible upon terlipressin withdrawal.

23 Sep 2010

Hypertension (High Blood Pressure) News and Research

Further Reading

Jiangbo fourth-quarter revenues decrease 5.9% to $29.3M

Tengion presents Neo-Kidney Augment development program at ISCT Symposium

Pulmokine receives NIH SBIR grants to develop novel treatments for PAH

Hypertension drug market to decline by $3 billion in 2019: Decision Resources

Endo Pharmaceuticals to acquire Qualitest Pharmaceuticals

Women & Infants Hospital receives $2.1M NIH grant to continue work under COBRE for Perinatal Biology

Experts predict rise in food prices

Clinical trial results of Genous Bio-engineered R stent, EPC capture technology presented at TCT 2010

HHS awards grant to promote better primary care services for mentally-ill patients

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

Malnutrition, inflammation complicate blood cholesterol readings in CKD patients

Preclinical data of novel drug-resistant hypertension therapy presented at TCT 2010

UC San Diego receives grant to study hypoxia susceptibility

Scientists discover molecular playbook to block cardiac hypertrophy

Negative childhood experiences impacting in the brains of Indigenous kids

Physicians' health habits could affect their abilities to counsel patients on diet, exercise

Resistance training program can help maintain metabolic health: Research

Phase II study: Fostamatinib improves outcomes in RA patients

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

Hyponatremia may lead to neurological complications

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News